Jefferies Cuts Price Target on Anacor Pharma (ANAC) to $105 Following a 4Q EPS Miss
Tweet Send to a Friend
Jefferies maintained a Buy rating on Anacor Pharmaceuticals (NASDAQ: ANAC), and cut the price target to $105.00 (from $159.00), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
